Over the last few years, Curetis has created a down-to-earth and continuous success story. It all began with the Unyvero product idea and progressed through the development and approval procedure towards tapping into the international medical technology markets. From the outset, the company has impressed with its high awareness of quality combined with a strong pioneering spirit and the simple claim: "We care for diagnostics". This success was due, in no small part, to the outstanding engineering capabilities and molecular and microbiological expertise of both our investors and our customers and partners.
Curetis' growth potential lies, on the one hand, in developing and expanding the world's national markets and, on the other hand, in extending the Unyvero system with a continuous stream of new cartridges for additional infectious diseases.
Subscribe to Curetis Newsletter
Curetis Announces Financial Results for the First Nine Months of 2018
Curetis Accelerates 510(k) Submission Preparation for Unyvero LRT in BAL Specimen Based on Positive FDA Feedback
38ème Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse - Paris, France - December 17 to 18, 2018
DIVI 2018- December 5 to 7, 2018, Leipzig, Germany